NATCO Pharma (NATCOPHARM) Q4 23/24 earnings summary

Executive summary

• FY24 consolidated total income reached INR 41,269 mn, up 46.8% YoY; net profit rose 94.1% to INR 13,883 mn, both records.

• Q4 consolidated revenue from operations was INR 10,683 mn and net profit was INR 3,863 mn.

• FY24 EBITDA was INR 18,795 mn, with a 45.5% margin; both figures include other income.

Financial highlights

• FY24 consolidated revenue from operations was INR 39,988 mn vs INR 27,071 mn; PBT was INR 16,735 mn vs INR 8,619 mn.

• Q4 consolidated revenue from operations was INR 10,683 mn vs INR 8,979 mn; net profit was INR 3,863 mn vs INR 2,758 mn.

• Total revenue was INR 11,103 mn in Q4FY24 vs INR 9,269 mn, and INR 41,269 mn in FY24 vs INR 28,117 mn in FY23.

• EBITDA was INR 5,393 mn in Q4FY24 vs INR 3,681 mn, and INR 18,795 mn in FY24 vs INR 10,402 mn; PAT was INR 3,863 mn vs INR 2,758 mn and INR 13,883 mn vs INR 7,153 mn, respectively.

Segment performance

• FY24 Pharmaceuticals revenue was INR 38,905 mn vs INR 26,662 mn; segment results were INR 17,523 mn vs INR 8,884 mn.

• FY24 export formulations revenue was INR 32,369 mn vs INR 20,632 mn; Q4FY24 revenue was INR 9,549 mn vs INR 7,092 mn.

• FY24 domestic formulations revenue was INR 3,867 mn vs INR 3,749 mn; Q4FY24 revenue was INR 524 mn vs INR 918 mn.

• FY24 Agro chemicals revenue was INR 1,083 mn vs INR 409 mn; segment loss widened to INR 596 mn from INR 120 mn.

• Q4 Pharmaceuticals revenue was INR 10,746 mn and segment results were INR 5,368 mn; Agro chemicals revenue was negative INR 63 mn and segment loss was INR 530 mn.